Hangzhou Eli Radiopharma Co., Ltd. raised nearly CN¥400 million in a Series A funding round. Huagai Capital led the round, and Bayland Capital served as co-lead. The company develops radiopharmaceuticals for oncology and neurological diseases.
Investor backing
Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, and Bairui Capital joined the round. Shenzhen Angel FOF Management and Grand Flight Investment also participated. Existing backers included CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund, and Skyfield Capital.
Company focus
Eli Radiopharma was founded in 2024 and is based in Hangzhou. It focuses on next-generation radiopharmaceuticals and advanced technology applications. The company combines molecular targeting with radionuclide technology for theranostic solutions.
Pipeline plans
The new funding will support preclinical research, clinical trial applications, and early-stage clinical development. It will also back R&D platforms, talent acquisition, and clinical and business development. Several programs are approaching IND submission.
The company plans to use the funds to move lead programs through preclinical development and regulatory milestones. It also aims to deliver precision diagnostic and therapeutic options for patients with cancer and neurological diseases. Future work will include expanding its team and technology platforms.